Market Research Logo

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Pipeline Review, H1 2018

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Pipeline Review, H1 2018

Summary

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) pipeline Target constitutes close to 10 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

The latest report Dual Specificity Protein Kinase TTK - Pipeline Review, H1 2018, outlays comprehensive information on the Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Dual specificity protein kinase TTK is an enzyme encoded by the TTK gene. It is associated with cell proliferation, essential for chromosome alignment at the centromere during mitosis and is required for centrosome duplication.

It acts as critical mitotic checkpoint protein for accurate segregation of chromosomes during mitosis. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 3 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Breast Cancer, Metastatic Breast Cancer, Solid Tumor, Colorectal Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and Pancreatic Ductal Adenocarcinoma.

Furthermore, this report also reviews key players involved in Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1)
  • The report reviews Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Overview
Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Companies Involved in Therapeutics Development
Bayer AG
Boston Pharmaceuticals Inc
Les Laboratoires Servier SAS
Nerviano Medical Sciences Srl
Netherlands Translational Research Center BV
Pfizer Inc
Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Drug Profiles
BAY-1161909 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1217389 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOS-172722 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-271850 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CFI-402257 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-153 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-715 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTRC-00660 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mps1 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Tyrosine Threonine Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Dormant Products
Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Discontinued Products
Dual Specificity Protein Kinase TTK (Cancer/Testis Antigen 96 or Monopolar Spindle 1 Like 1 or Phosphotyrosine Picked Threonine Protein Kinase or TTK or EC 2.7.12.1) - Product Development Milestones
Featured News & Press Releases
Apr 20, 2017: Experimental drug could lead to potent combination in breast and other cancers
Sep 24, 2015: Servier and Nerviano Medical Sciences announce the entry of S 81694, an MPS1 inhibitor, in a first in Human clinical trial
Oct 29, 2012: Nerviano Medical Sciences To Present Four Posters At 24th EORTC-NCI-AACR Symposium
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Bayer AG, H1 2018
Pipeline by Boston Pharmaceuticals Inc, H1 2018
Pipeline by Les Laboratoires Servier SAS, H1 2018
Pipeline by Nerviano Medical Sciences Srl, H1 2018
Pipeline by Netherlands Translational Research Center BV, H1 2018
Pipeline by Pfizer Inc, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report